Top Image
Advanced Centre for Treatment Research & Education in Cancer
Facebook Twitter Gmail
Banner Image
Science Sparks @ ACTREC
Date Image 2nd May 2022 Vol. No. 11; Issue No. 524

1. dos-Santos-Silva I, Gupta S, Orem J (2022). Shulman L Global disparities in access to cancer care. Communications Medicine. 2:31.

2. Saju AC, Chatterjee A, Sahu A, Gupta T, Krishnatry R, Mokal S, Sahay A, Epari S, Prasad M, Chinnaswamy G, Agarwal JP, Goda JS (2022). Machine-learning approach to predict molecular subgroups of medulloblastoma using multiparametric MRI-based tumor radiomics. British Journal of Radiology. 23: 20211359.

3. Kumar R, Abreu C, Toi M, Saini S, Casimiro S, Arora A, Paul AM, Velaga R, Rameshwar P, Lipton A, Gupta S, Costa L (2022). Oncobiology and treatment of breast cancer in young women. Cancer and Metastasis Reviews.

Site of the Week

ESTScan is a program that can detect coding regions in DNA sequences, even if they are of low quality. It will also detect and correct sequencing errors that lead to frameshifts.

desktop Image
Interesting Reads

Baek M, Chai JC, Choi HI, Yoo E, Binas B, Lee YS, Jung KH, Chai YG. Comprehensive transcriptome profiling of BET inhibitor-treated HepG2 cells. PLoS One. 17(4):e0266966, 2022.

Legends of Science
Seyed Ehtesham Hasnain Seyed Ehtesham Hasnain

Seyed Ehtesham Hasnain obtained his Ph.D. from the Jawaharlal Nehru University, New Delhi. His primary contribution has been gene expression, genetic analysis of polymorphism, and molecular functional epidemiology/ infection biology. His research on molecular epidemiology of the TB bacterium has led to understanding dissemination dynamics and identification of the predominant strains circulating in India. It resulted in the title of several novel diagnostics markers and drug targets for TB. Dr. Hasnain received the SS Bhatnagar Award in 1995; GD Birla Award in 2001; Shri Om Prakash Bhasin Award in 2004; Padma Shri in 2006. He is a fellow of the Indian Academy of Sciences, Bangalore; National Academy of Sciences, Allahabad.

Raghavendra Gadagkar Raghavendra Gadagkar

Raghvendra Gadagkar received his Ph.D. from the Indian Institute of Science in 1979. He has significantly contributed to animal behavior, ecology, behavioral ecology, and socio-biology and statistics. The prime subject of his research is the origin and evolution of cooperation in animals and social insects, such as ants, bees, and wasps. Dr. Gadagkar is a recipient of the SS Bhatnagar Award in 1993; Homi Bhabha Fellowship; BP Pal National Environment Fellowship on Biodiversity. He is an elected Fellow of the Indian Academy of Sciences, Bangalore; National Academy of Sciences, Allahabad; Foreign Associate of the National Academy of Science, USA and the German National Science Academy, Leopoldina.

Upcoming Events
The 8th World Congresses on Controversies in Multiple Myeloma

12-14 May, 2022

At Paris, France.

Congress of the International Society of Ocular Oncology

17-21 June, 2022

At Leiden, The Netherlands

4th Indo Oncology Summit 2022

23-25 September, 2022

At Bhubaneswar, India

Do You Know?

In 1891, William Coley, a surgeon at Memorial Sloan Kettering, pioneered the first nonsurgical treatment of cancer through an early form of immunotherapy. He treats sarcoma with the toxins of a bacterial skin infection to rally the body’s natural defenses against cancer.

back Image
Cancer News
A promising combination therapy for triple-negative breast cancer

27 April 2022, EurekAlert

Researchers at Baylor College of Medicine and collaborating institutions have identified a combination therapy for treating triple-negative breast cancer (TNBC) that results in durable tumor regression in an animal model of the condition...

CAR T drives acute myeloid leukemia into submission in pre-clinical studies

28 April 2022, ScienceDaily

Investigators have devised a novel method for improving CAR T therapy through a drug combination and cellular engineering that improves the strength and durability of the tumor-killing effect of a CAR T directed against acute myeloid leukemia...

Gut microbiome may alter response to cancer therapy

28 April 2022, MedicalXpress

Researchers report on an emerging role for gut microbiota in immunotherapy. Immune checkpoint inhibitors and immune checkpoint blockade therapy are novel strategies for treating cancer, but response to these forms of treatment varies considerably between individuals and across cancer types...

� 2022 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)